Mark The Medic's Blog 🚑🚑🚑

Home » Uncategorized » JEXT Pen RECALL

JEXT Pen RECALL

Advertisements

ALK-Abelló recalls some batches of Jext® adrenaline auto-injectors in the United Kingdom

ALK-Abelló is recalling certain batches of Jext®adrenaline auto-injector, 150 microgram and 300 microgram, at patient level in the UK. The class 2 recall affects 66,813 Jext® produced from March 2013 to October 2013. Please see the list of affected batches below.

Downloadable information for Doctors, Pharmacists and Patients

DoctorsPharmacistsPatients

Jext® is a single-use adrenaline auto-injector intended for the emergency treatment of severe acute allergic reactions (anaphylaxis) to insect stings or bites, foods, drugs and other allergens as well as idiopathic or exercise induced anaphylaxis.

A routine testing conducted by ALK-Abelló has revealed that during the production process of these batches the needle may have become bent, causing the needle to curl up inside the injector housing upon activation and consequently causing the pen not to deliver the required adrenaline dose. The malfunction only affects a small percentage (0.04%) of the pens in these batches. Immediate action has been taken to eliminate similar production issues in the future.

Batch number and expiry date of the Jext® batches recalled in the United Kingdom:

Batch Number Description Expiry date
0000907947 Jext 150 µg           30-04-2015
0000884202 Jext 150 µg           31-03-2015
0000862719 Jext 150 µg           28-02-2015
0000853456 Jext 150 µg           28-02-2015
0000890991 Jext 150 µg           28-02-2015
0000804924 Jext 150 µg           31-01-2015
0000785381 Jext 150 µg           31-01-2015
0000748008 Jext 150 µg           31-12-2014
0000900033 Jext 300 µg           30-04-2015
0000874587 Jext 300 µg           28-02-2015
0000858432 Jext 300 µg           28-02-2015
0000860701 Jext 300 µg           28-02-2015
0000837516 Jext 300 µg           28-02-2015
0000874585 Jext 300 µg           28-02-2015
0000829690 Jext 300 µg           31-01-2015
0000810356 Jext 300 µg           31-01-2015
0000800083 Jext 300 µg           31-01-2015
0000774775 Jext 300 µg           31-01-2015
0000780782 Jext 300 µg           31-01-2015
0000750808 Jext 300 µg           31-12-2014
0000733979 Jext 300 µg           31-12-2014

Patients are advised to check the batch number printed on the pen and the cardboard box to find out if their Jext® pen is affected by the recall:

Patients carrying a Jext® with a batch number not mentioned above can continue to carry their Jext® for emergency treatment of severe acute allergic reactions (anaphylaxis).

Advice to patients carrying a Jext® pen with one of the above-mentioned batch numbers

Patient carrying a Jext® with one of the above-mentioned batch numbers are advised to obtain a replacement adrenaline auto-injector from their doctor as soon as this is practically possible. Patients are advised to continue to carry and use their Jext® as normal until they are able to obtain a replacement adrenaline auto-injector. Patients should ensure they understand how to use the replacement auto-injector correctly as it may be different from Jext®.

If a patient suffers anaphylaxis before they have obtained a replacement adrenaline auto-injector from their health care professional, they are advised to use their Jext® as instructed by the prescribing doctor.

The safety of patients is our priority concern at ALK-Abelló and we are committed to delivering only high-quality products. ALK-Abelló takes the potential malfunction of some our adrenalin pens very seriously and has therefore immediately initiated a dialogue with the authorities regarding a recall. ALK-Abelló has also taken immediate action to eliminate similar production issues in the future.

ALK-Abelló is working with the Department of Health to minimise the financial consequences of this recall.

About Jext®

Jext® is a single-use adrenaline auto-injector and is indicated in the emergency treatment of severe acute allergic reactions (anaphylaxis) to insect stings or bites, foods, drugs and other allergens as well as idiopathic or exercise induced anaphylaxis. Jext® was developed by ALK-Abelló and approved in the United Kingdom in 2010. The product has been marketed since 2011. Jext® is produced in Europe by ALK-Abelló and subcontractors.

Further information

ALK-Abelló Ltd
1 Manor Park
Manor Farm Road
Berkshire
RG2 0NA
T: 0800 028 3144
e-mail: info@uk.alk-abello.com

Advertisements

1 Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: